患者来源类器官支持食管鳞癌放疗反应和复发风险预测
Patient-derived organoids support radiotherapy response and recurrence risk prediction in esophageal squamous cancer.
作者
作者单位
- Central R&D Center, Medical & Bio Decision (MBD) Co., Ltd, Suwon, Republic of Korea.
- Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon, Republic of Korea.
- Department of Biomedical Engineering, Gachon University, Seongnam, Republic of Korea.
摘要
中文
预测个体对放疗的反应仍是食管癌的一大挑战。本研究评估了一种基于癌症类器官的诊断和反应预测（CODRP）方法，用于预测食管鳞状细胞癌新辅助放化疗（NCRT）后的病理反应和复发风险。类器官从内镜活检标本中建立，并以2、4或8 Gy的剂量照射。定量基于生长抑制的曲线下面积（GI-AUC）和细胞生长速率，并与临床癌症分期整合产生CODRP指数。与单参数模型相比，CODRP在该可行性队列中显示出改善的病理反应预测表现（敏感性87.5%，特异性100%）。CODRP分类为放射敏感组的无复发生存期（71.43%）显著高于放射抵抗组（10%）（p=0.0103）。这些发现支持CODRP在食管鳞状细胞癌放疗反应和复发风险预测中的可行性。
English
Predicting individual responses to radiotherapy remains a major challenge in esophageal cancer. This study evaluated an cancer organoid-based diagnosis and reactivity prediction (CODRP) approach to estimate pathological response and recurrence risk after neoadjuvant chemoradiotherapy (NCRT) in esophageal squamous cell carcinoma. Organoids were established from endoscopic biopsy specimens and irradiated with doses of 2, 4, or 8 Gy. Growth inhibition-based area under the curve (GI-AUC) and cell growth rates were quantified and integrated with the clinical cancer stage to generate the CODRP index. Compared with single-parameter models, the CODRP showed improved apparent predictive performance for pathological response prediction in this feasibility cohort (sensitivity, 87.5%; specificity, 100%). Recurrence-free survival was significantly higher in the CODRP-classified radiation-sensitive group (71.43%) than in the radiation-resistant group (10%) (p = 0.0103). These findings support the feasibility of applying CODRP to radiotherapy response and recurrence risk prediction in esophageal squamous cell carcinoma.
分类与指标
- 研究类型
- 临床研究
- 病种
- 食管癌
- JCR 分区
- Q1
- 影响因子
- 4.5
- 新锐分区
- 3区